CNSC issues BWXT Medical Ltd. a Class IB nuclear substance processing facility licence to operate the Nuclear Medicine Production Facility
October 15, 2021 – Ottawa
Today, the Canadian Nuclear Safety Commission (CNSC) announced its decision to issue BWXT Medical Ltd. (BWXT Medical) a Class IB nuclear substance processing facility licence to operate the Nuclear Medicine Production Facility (NMPF) in Ottawa, Ontario. Until this decision, the NMPF was 1 of 2 production facilities operated by Nordion (Canada) Inc. under its own separate licence. This decision follows a public hearing held virtually on June 9, 2021. The licence allows BWXT Medical to process a variety of radioisotopes used in nuclear medicine at the NMPF.
In making its decision, the Commission considered submissions from BWXT Medical and 21 intervenors, as well as CNSC staff recommendations. The CNSC made participant funding available through its Participant Funding Program, and invited interventions from Indigenous groups, members of the public and stakeholders in this matter. Five requesters received participant funding to assist with their interventions.
After reviewing all submissions, the Commission concluded that BWXT Medical is qualified to carry out the nuclear processing activities that the new licence will authorize. It also concluded that BWXT Medical will make adequate provision for the protection of the environment, and the health and safety of persons.
The record of decision is available on request to the Commission Secretariat at firstname.lastname@example.org. The decision will also be posted in both official languages at nuclearsafety.gc.ca at a later date. All submissions, hearing transcripts and the hearing webcast are available on the CNSC website.
The CNSC regulates the use of nuclear energy and materials to protect health, safety, security and the environment; to implement Canada’s international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public.
- BWXT Medical applied for a licence in December 2018.
- The CNSC made funding available in November 2020 through the Participant Funding Program to support Indigenous peoples, members of the public and stakeholders in presenting their views to the Commission.
- The Commission held a virtual public hearing on June 9, 2021 (hearing transcripts and webcast are available online or by request).
- The licence is valid until October 31, 2031.
The NMPF has been in operation since 1982.
BWXT Medical acquired Nordion’s medical isotope business, including the equipment and personnel of the NMPF, in 2018.
BWXT Medical intends to resume the production of molybdenum-99 (Mo-99) at the NMPF using a new process that is currently under development.
CNSC staff must report on the performance of BWXT Medical and the NMPF through regulatory oversight reports at the Commission’s public proceedings.
Indigenous peoples, members of the public and stakeholders will be invited to participate in these Commission proceedings.
Canadian Nuclear Safety Commission
Tel: 613-996-6860 or 1-800-668-5284
Report a problem or mistake on this page
- Date modified: